EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY

by I. V. Shirinsky, O. I. Zheltova, V. S. Shirinsky, V. A. Kozlov
Published 2014-07-01

Update on immunopathogenesis and immunotherapy in multiple sclerosis

by Selter RC, Hemmer B
Published 2013-04-01

Disease-Modifying Therapy for Transthyretin Amyloidosis

by Nowell M. Fine, MD, SM
Published 2020-11-01

EFFICIENCY OF TRIPLE (METHOTREXATE + SULFASALAZINE + HYDROXYCHLOROQUINE) COMBINATION DISEASE-MODIFYING THERAPY VERSUS METOTREXATE MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS

by E E Gubar', A G Bochkova, N V Bunchuk, E E Gubar, A G Bochkova, N V Bunchuk
Published 2011-04-01

Promises and pitfalls of immune-based strategies for Huntington's disease

by Gabriela Delevati Colpo, Erin Furr Stimming, Natalia Pessoa Rocha, Antonio Lucio Teixeira
Published 2017-01-01

Outcomes of pregnancy in Egyptian women with multiple sclerosis in the new treatment era: a multi-center retrospective observational study

by Ali Mahmoud Ahmed, Mohamed Al-Bahay M. G. Reda, Ahmed Hassan Elsheshiny
Published 2021-09-01

Leflunomide (Arava) in early rheumatoid arthritis

by R V Balabanova, D E Karateev, R YKashevarov, E L Luchihina
Published 2005-10-01

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations

by Brian Barry, April A. Erwin, Jessica Stevens, Carlo Tornatore
Published 2019-11-01

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

by Annette F. Okai, Lilyana Amezcua, Regina R. Berkovich, Angel R. Chinea, Keith R. Edwards, Brian Steingo, Aljoeson Walker, Alan K. Jacobs, Nadia Daizadeh, Mitzi J. Williams, the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
Published 2019-10-01

Novas perspetivas no tratamento farmacológico da miocardiopatia hipertrófica

by Sérgio Maltês, Luis Rocha Lopes
Published 2020-02-01

Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy’s Impact on Disease Activity

by Guoda Varytė, Jolita Zakarevičienė, Diana Ramašauskaitė, Dalia Laužikienė, Audronė Arlauskienė
Published 2020-01-01

The Effects of Multiple Sclerosis and Disease Modifying Therapy on Pregnancy

by Tarneer Kaur Johal
Published 2017-12-01

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort

by Melesse DY, Marrie RA, Blanchard JF, Yu BN, Evans C
Published 2017-06-01

Examining adherence, perceptions, and symptoms in patients with Multiple Sclerosis

by Suh, Kangho
Published 2013

6-Month Effectiveness Safety and Tolerability of Ocrelizumab and Comparative Safety with Rituximab

by Moss, Brandon Price
Published 2020

Bilirubin: A Promising Therapy for Parkinson’s Disease

by Sri Jayanti, Rita Moretti, Claudio Tiribelli, Silvia Gazzin
Published 2021-06-01

Clinical efficacy and safety of alemtuzumab in postmarketing practice

by N. V. Khachanova
Published 2019-06-01

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis

by Fronza M, Lorefice L, Frau J, Cocco E
Published 2021-05-01

BRAIN ATROPHY AS A MEASURE OF NEUROPROTECTIVE DRUG EFFECTS IN MULTIPLE SCLEROSIS: INFLUENCE OF INFLAMMATION

by Tatiana eKoudriavtseva, Caterina eMainero
Published 2016-05-01

Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients

by Nick Bansback, Judy A. Chiu, Robert Carruthers, Rebecca Metcalfe, Emmanuelle Lapointe, Alice Schabas, Marilyn Lenzen, Larry D. Lynd, Anthony Traboulsee
Published 2019-07-01